Please try another search
Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. Its leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. The company also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, it provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is headquartered in Burnaby, Canada.
Name | Age | Since | Title |
---|---|---|---|
Benjamin Lightburn | 36 | 2020 | Co-Founder, CEO & Chairman |
Jonathan Conlin | 39 | 2021 | Corporate Secretary & Director |
Joshua Woolley | - | - | Member of Advisory Council |
Konstantin Adamsky | 53 | 2022 | Independent Director |
Michael Messinger | 49 | 2024 | Director |
Jeff Chilton | - | 2022 | Member of Advisory Council |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review